eXoZymes (EXOZ) Competitors

$9.77 -0.25 (-2.50%)

Closing price 05/15/2026 03:58 PM Eastern

Extended Trading

$9.36 -0.41 (-4.24%)

As of 05/15/2026 04:02 PM Eastern

EXOZ vs. SLN, ORGO, FBRX, IMRX, and NVCT

Should you buy eXoZymes stock or one of its competitors? MarketBeat compares eXoZymes with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with eXoZymes include Silence Therapeutics (SLN), Organogenesis (ORGO), Forte Biosciences (FBRX), Immuneering (IMRX), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.

How does eXoZymes compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

98.7% of Silence Therapeutics shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Silence Therapeutics currently has a consensus price target of $55.00, indicating a potential upside of 801.64%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

eXoZymes has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -105.34% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
eXoZymes	N/A	-181.27%	-124.17%

In the previous week, Silence Therapeutics had 6 more articles in the media than eXoZymes. MarketBeat recorded 9 mentions for Silence Therapeutics and 3 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.08 beat Silence Therapeutics' score of 0.99 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Silence Therapeutics	Positive
eXoZymes	Positive

Silence Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.85, suggesting that its stock price is 185% more volatile than the broader market.

eXoZymes has lower revenue, but higher earnings than Silence Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	514.47	-$88.61M	-$1.59	N/A
eXoZymes	N/A	N/A	-$9.16M	-$1.14	N/A

Summary

Silence Therapeutics beats eXoZymes on 10 of the 16 factors compared between the two stocks.

How does eXoZymes compare to Organogenesis?

eXoZymes (NASDAQ:EXOZ) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

49.6% of Organogenesis shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 33.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Organogenesis has a consensus price target of $8.50, suggesting a potential upside of 252.70%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts clearly believe Organogenesis is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

eXoZymes has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-181.27%	-124.17%
Organogenesis	-0.84%	9.63%	4.76%

In the previous week, eXoZymes had 2 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for eXoZymes and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.89 beat eXoZymes' score of 1.08 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
eXoZymes	Positive
Organogenesis	Very Positive

eXoZymes has a beta of 2.85, suggesting that its share price is 185% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

Organogenesis has higher revenue and earnings than eXoZymes. Organogenesis is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	N/A	N/A	-$9.16M	-$1.14	N/A
Organogenesis	$512.59M	0.60	$37.03M	-$0.19	N/A

Summary

Organogenesis beats eXoZymes on 10 of the 15 factors compared between the two stocks.

How does eXoZymes compare to Forte Biosciences?

eXoZymes (NASDAQ:EXOZ) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

eXoZymes has a beta of 2.85, meaning that its stock price is 185% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

In the previous week, Forte Biosciences had 10 more articles in the media than eXoZymes. MarketBeat recorded 13 mentions for Forte Biosciences and 3 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.08 beat Forte Biosciences' score of 0.78 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forte Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Forte Biosciences' return on equity of -106.17% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-181.27%	-124.17%
Forte Biosciences	N/A	-106.17%	-85.50%

Forte Biosciences has a consensus price target of $67.00, suggesting a potential upside of 189.92%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Forte Biosciences is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

77.6% of Forte Biosciences shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

eXoZymes is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	N/A	N/A	-$9.16M	-$1.14	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Summary

Forte Biosciences beats eXoZymes on 9 of the 13 factors compared between the two stocks.

How does eXoZymes compare to Immuneering?

eXoZymes (NASDAQ:EXOZ) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

eXoZymes is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	N/A	N/A	-$9.16M	-$1.14	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.38	N/A

eXoZymes has a beta of 2.85, meaning that its stock price is 185% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

In the previous week, Immuneering had 1 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Immuneering and 3 mentions for eXoZymes. Immuneering's average media sentiment score of 1.22 beat eXoZymes' score of 1.08 indicating that Immuneering is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering's return on equity of -43.33% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-181.27%	-124.17%
Immuneering	N/A	-43.33%	-39.75%

Immuneering has a consensus price target of $16.50, suggesting a potential upside of 219.77%. Given Immuneering's stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

67.7% of Immuneering shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 22.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Immuneering beats eXoZymes on 10 of the 14 factors compared between the two stocks.

How does eXoZymes compare to Nuvectis Pharma?

eXoZymes (NASDAQ:EXOZ) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

eXoZymes is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	N/A	N/A	-$9.16M	-$1.14	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

eXoZymes has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market.

In the previous week, eXoZymes had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 3 mentions for eXoZymes and 2 mentions for Nuvectis Pharma. eXoZymes' average media sentiment score of 1.08 beat Nuvectis Pharma's score of 0.94 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma's return on equity of -161.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-181.27%	-124.17%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Nuvectis Pharma has a consensus price target of $10.00, suggesting a potential downside of 9.42%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Nuvectis Pharma is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.8% of Nuvectis Pharma shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 30.5% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Nuvectis Pharma beats eXoZymes on 7 of the 13 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXOZ vs. The Competition

Export

Metric	eXoZymes	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$82.76M	$3.31B	$6.37B	$12.30B
Dividend Yield	N/A	2.32%	2.80%	5.26%
P/E Ratio	-8.57	18.50	20.66	25.27
Price / Sales	N/A	179.00	532.18	61.69
Price / Cash	N/A	121.77	42.43	54.86
Price / Book	24.42	6.63	9.87	6.90
Net Income	-$9.16M	$24.40M	$3.57B	$334.66M
7 Day Performance	-2.65%	4.14%	0.23%	0.12%
1 Month Performance	-9.29%	-4.80%	-2.54%	-0.18%
1 Year Performance	-35.05%	62.87%	33.54%	30.62%

eXoZymes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXOZ eXoZymes	0.3577 of 5 stars	$9.77 -2.5%	N/A	-35.0%	$82.76M	N/A	N/A	29	News Coverage Earnings Report
SLN Silence Therapeutics	2.8875 of 5 stars	$6.10 -14.4%	$55.00 +801.6%	+39.6%	$336.78M	$560K	N/A	100	Earnings Report Analyst Revision
ORGO Organogenesis	2.7393 of 5 stars	$2.41 -6.9%	$8.50 +252.7%	-21.8%	$333.27M	$564.17M	N/A	950
FBRX Forte Biosciences	2.2745 of 5 stars	$23.11 -3.5%	$67.00 +189.9%	+194.4%	$332.70M	N/A	N/A	5	Trending News Earnings Report Upcoming Earnings Options Volume Analyst Revision Gap Down
IMRX Immuneering	2.2962 of 5 stars	$5.16 +0.4%	$16.50 +219.8%	+258.3%	$332.54M	N/A	N/A	60	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXOZ) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

eXoZymes (EXOZ) Competitors

EXOZ vs. SLN, ORGO, FBRX, IMRX, and NVCT

How does eXoZymes compare to Silence Therapeutics?

Summary

How does eXoZymes compare to Organogenesis?

Summary

How does eXoZymes compare to Forte Biosciences?

Summary

How does eXoZymes compare to Immuneering?

Summary

How does eXoZymes compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

eXoZymes (EXOZ) Competitors

EXOZ vs. SLN, ORGO, FBRX, IMRX, and NVCT

How does eXoZymes compare to Silence Therapeutics?

Do insiders and institutionals have more ownership in SLN or EXOZ?

Do analysts recommend SLN or EXOZ?

Is SLN or EXOZ more profitable?

Does the media refer more to SLN or EXOZ?

Which has more risk & volatility, SLN or EXOZ?

Which has preferable valuation and earnings, SLN or EXOZ?

Summary

How does eXoZymes compare to Organogenesis?

Do insiders and institutionals have more ownership in EXOZ or ORGO?

Do analysts prefer EXOZ or ORGO?

Is EXOZ or ORGO more profitable?

Does the media prefer EXOZ or ORGO?

Which has more volatility and risk, EXOZ or ORGO?

Which has better valuation & earnings, EXOZ or ORGO?

Summary

How does eXoZymes compare to Forte Biosciences?

Which has more risk and volatility, EXOZ or FBRX?

Does the media prefer EXOZ or FBRX?

Is EXOZ or FBRX more profitable?

Do analysts rate EXOZ or FBRX?

Do institutionals and insiders have more ownership in EXOZ or FBRX?

Which has preferable valuation and earnings, EXOZ or FBRX?

Summary

How does eXoZymes compare to Immuneering?

Which has preferable valuation and earnings, EXOZ or IMRX?

Which has more risk and volatility, EXOZ or IMRX?

Does the media prefer EXOZ or IMRX?

Is EXOZ or IMRX more profitable?

Do analysts rate EXOZ or IMRX?

Do institutionals and insiders have more ownership in EXOZ or IMRX?

Summary

How does eXoZymes compare to Nuvectis Pharma?

Which has better earnings and valuation, EXOZ or NVCT?

Which has more risk & volatility, EXOZ or NVCT?

Does the media favor EXOZ or NVCT?

Is EXOZ or NVCT more profitable?

Do analysts rate EXOZ or NVCT?

Do insiders & institutionals have more ownership in EXOZ or NVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools